The effect of direct access to CT scan in early lung cancer detection: an unblinded, cluster-randomised trial by Louise Mahncke Guldbrandt et al.
RESEARCH ARTICLE Open Access
The effect of direct access to CT scan in
early lung cancer detection: an unblinded,
cluster-randomised trial
Louise Mahncke Guldbrandt1,2*, Morten Fenger-Grøn1, Torben Riis Rasmussen3, Finn Rasmussen4,
Peter Meldgaard5 and Peter Vedsted1
Abstract
Background: Lower lung cancer survival rates in Britain and Denmark compared with surrounding countries may,
in part, be due to late diagnosis. The aim of this study was to evaluate the effect of direct access to low-dose
computed tomography (LDCT) from general practice in early lung cancer detection on time to diagnosis and stage
at diagnosis.
Methods: We conducted a cluster-randomised, controlled trial including all incident lung cancer patients (in 19-month
period) listed with general practice in the municipality of Aarhus (300,000 citizens), Denmark. Randomisation and
intervention were applied at general practice level. A total of 266 GPs from 119 general practices. In the study period,
331 lung cancer patients were included. The intervention included direct access to low-dose CT from primary care
combined with a 1 h lung cancer update meeting. Indication for LDCT was symptoms or signs that raised the GP’s
suspicion of lung cancer, but fell short of satisfying the fast-track referral criteria on red flag’ symptoms.
Results: The intervention did not significantly influence stage at diagnosis and had limited impact on time to
diagnosis. However, when correcting for non-compliance, we found that the patients were at higher risk of
experiencing a long diagnostic interval if their GPs were in the control group.
Conclusion: Direct low-dose CT from primary care did not statistically significantly decrease time to diagnosis or
change stage at diagnosis in lung cancer patients. Case finding with direct access to LDCT may be an alternative
to lung cancer screening. Furthermore, a recommendation of low-dose CT screening should consider offering
symptomatic, unscreened patients an access to CT directly from primary care.
Trial registration: www.clinicaltrials.gov, registration ID number NCT01527214.
Background
Lung cancer is the most common cause of cancer death
in the industrialised world [1]. The stage of the disease
profoundly predicts survival. Efforts to diagnose lung
cancer early have included screening initiatives [2, 3]
and expedited investigation of symptoms indicative of
lung cancer [4–6]. Although screening might reduce
mortality from lung cancer in relative terms, it remains
very doubtful that such a strategy will be implemented
worldwide.
So far, most lung cancer patients with symptomatic
disease present to the general practitioner (GP) before
diagnosis [7, 8]. Symptoms that may indicate lung cancer
are common in primary care [9]. GPs must distinguish
between those few patients whose symptoms are due to
lung cancer and the large group of patients who have
benign disease [10]. For many of these symptomatic
patients, the ideal strategy might not be a full fast-track
referral, but easy access to a relevant investigation in
general practice.
Patients in Britain and Denmark have lower survival
from lung cancer and fewer are diagnosed in the early
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stages compared with other European countries (11).
Much effort has therefore been devoted to achieving
earlier diagnosis of lung cancer. British and Danish ini-
tiatives to expedite cancer diagnosis have included clin-
ical initiatives (e.g. National Institute for Health and
Care Excellence (NICE) guidelines for symptoms in the
UK) as well as organisational initiatives (e.g. fast-track
referral pathway in Denmark [11, 12]).
However, essentially three difficulties have been re-
vealed; a significant proportion of lung cancer patients
present with unspecific symptoms with low positive pre-
dictive values [13], the majority of lung cancer patients
are diagnosed by other routes than the expedited one
[14, 15], and there may be a need for a technological up-
date of the primary diagnostic investigation which has
been the chest X-ray. Thus, 15–23 % of all new lung
cancer patients have had a false-negative chest X-ray be-
fore diagnosis, which has important implications for the
time to diagnosis [16] and challenges the traditional pri-
mary care investigation. A low-dose computed tomog-
raphy (LDCT), on the other hand, has proven to have a
high sensitivity for lung cancer [17], even in early-stage
cancer. However, we do not know whether direct access
to LDCT will optimise lung cancer diagnosis in symp-
tomatic patients seen by their GPs.
We hypothesised that GPs who had direct access to
LDCT and received an update on lung cancer detection
would diagnose lung cancer faster and at earlier stages.
Furthermore, we hypothesised that this intervention
would increase the GPs’ awareness of lung cancer and
make them increase their standard investigations (e.g.
fast-track use) for lung cancer.
The aim of this study was to evaluate the effect of dir-
ect access to fast low-dose chest CT combined with spe-
cific training in the diagnosis of lung cancer in general
practice on the time to diagnosis and the stage at diag-
nosis. Furthermore, we wanted to evaluate differences
between the intervention practices’ and the control prac-
tices’ use of fast-track investigation.
Methods
We conducted a cluster-randomised, controlled, two-
arm (1:1), unblinded study. The intervention was a
technological upgrade comprising direct access to chest
low-dose CT combined with a simple continuing med-
ical education (CME) meeting on lung cancer diagnos-
tics in general practice. The study took place in Aarhus
municipality, Denmark, during a 19-month period from
November 2011 to June 2013.
Denmark has a tax-financed healthcare system with
free access to medical advice and treatment. Approxi-
mately 99 % of Danish citizens are registered with a GP
whom they must consult for medical advice. GPs act as
gatekeepers to investigations and hospitals with a few
exceptions, e.g. emergencies.
Before November 2011, the GPs in the area had three
diagnostic work-up possibilities for patients with respira-
tory symptoms that could indicate lung cancer. They
could either refer patients to 1) an X-ray, 2) the Depart-
ment of Pulmonary Medicine within the normal waiting
list, or 3) the lung cancer fast-track pathway with a max-
imum of 72 h’ waiting time. Indication for fast-track was
either an abnormal chest X-ray or certain qualifying
‘red- flag’ symptoms (e.g. coughing (>four weeks) or
haemoptysis) [18]. GPs were not allowed to refer directly
to a CT.
Participants
A total of 119 general practices in the catchment area of a
single department of pulmonary medicine, Aarhus Univer-
sity Hospital, with 266 GPs were randomised into two
groups (Fig. 1). At patient level, the inclusion criteria were
that the patient was on the list of a participating GP dur-
ing the study period and had a recent diagnosis of lung
cancer (ICD10 34.0–9). There were no exclusion criteria.
Randomisation
The randomisation was performed by a data manager
who used Stata 12.0. The 119 practices were allocated a
random number between zero and one and then listed
from the lowest to the highest value. The top 60 practice
addresses (133 GPs) formed the intervention group with
practice addresses as cluster level.
Intervention
The intervention was allocated at the cluster level. Six
times within an initial 3-month period, the intervention
practices were informed by letter about the intervention.
The letters included information concerning the referral
procedures and indications for the CTs. The indication
was the GP’s suspicion that the patient’s signs and symp-
toms could possibly be related to lung cancer. Excepted
from this were patients who met the indication for fast-
track pathway referral who should be referred to the
fast-track as usual.
The GPs were offered participation in a 1 h small-
group-based CME meeting held during the first 2 months
of the study to increase their awareness of early lung
cancer and to encourage them to refer more patients to
tests (LDCT scan or fast-track pathway) for lung cancer.
During the meeting, the GPs were briefed about the
state-of-the-art on early detection of lung cancer based
on algorithms for positive predictive values in primary
care [13, 19]. The GPs also received information about
the use of CT and how to interpret CT reports. The edu-
cation was developed and conducted by PV and LMG.
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Controls were not informed about the study and they
hence continued referring their patients as usual.
The Department of Radiology, Aarhus University Hos-
pital, carried out the CTs. The scans were performed on a
Brilliance 64, Philips, Best, the Netherlands: collimation
64 × 0.625, slice thickness 2 mm, increment 1 mm, pitch 1,
rotation time 0.75 sec. The effective radiation dose (Monte
Carlo Simulation Software, CT-Expo v. 2.1) was 2–3 mSv.
Intravenous contrast medium was not administered. The
waiting time limit from referral to performed CT was a
maximum of two working days.
The CT reports were made by three sub-specialised
radiologists. Based on the CT report and the patient’s
medical history, a recommendation was compiled at a
conference between a chest physician and a radiologist
the day after the scan, and forwarded electronically to
the GP. The GP had full responsibility for informing the
patient about the result and, if necessary, to refer the pa-
tient for further diagnostic work-up.
If lung nodules (4–10 mm) that could not be categorised
as benign were detected, the GP was informed to refer the
patient to a follow-up program (3, 6 or 12 months after the
first scan) according to the size and the characteristics of
the nodules following the international standard [20]. Inci-
dental findings on the CT scan outside the lungs judged to
be of clinical significance were reported to the GP with rec-
ommendations for referral to a relevant department.
If the CT scan revealed any suspicion of lung cancer, the
patients were referred by the GP through the fast-track
pathway to standard diagnostic work-up at the Depart-
ment of Pulmonary Medicine. The diagnostic work-up in-
cluded contrast enhanced CT (including PET if surgery
was an option). Furthermore, a diagnosis was obtained by
either bronchoscopy with biopsy, fine-needle aspiration
(FNA) in association with endoscopic ultrasound or endo-
bronchial ultrasound, or transthoracic FNA. The final
clinical staging of lung cancer was provided by a multi-
disciplinary team decision according to the 7th TNM
Classification of Malignant Tumors [21]. Early-stage pa-
tients (stage I-IIb) were offered surgical resection accord-
ing to Danish guidelines.
Sample size
It can be assumed that lung cancer patients are randomly
distributed among GPs. However, the incidence of lung
cancer could be higher in some areas with many smokers
and in practices with many elderly patients. To account
for an unknown intra-cluster correlation coefficient (ICC),
we calculated a design effect of 1.25 [22].
In 2008 half of the Danish lung cancer patients waited
33 days or more (the median) from first presentation to
primary care to diagnosis of lung cancer [23]. We
wanted to be able to show a decrease in the diagnostic
interval to a level where only 25 % of the patients have
to wait 33 days or more. With a one-sided alpha of 5 %
and a power of 80 %, we had to include 54 lung cancer
patients in each arm with a 1:1 randomisation. Given
the design effect, we had to include a total of 135 lung
cancer patients with questionnaire data and GP involve-
ment in the diagnosis.
Harms
This intervention offered the GP an update on lung can-
cer and direct access to a CT scan. If the GP or the pa-
tient did not want to participate, they could always
choose not to. A potential harm was the extent of nod-
ules and incidental findings in the scans that may lead to
further examinations which ultimately could turn out to
be unnecessary if the findings were benign. The number
of derivative investigations after the low-dose CT scan
has been published previously [24].
Fig. 1 Participants flow. *Percentage of patients with questionnaire data
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Outcomes
Primary outcomes were the primary care interval and
the diagnostic interval. The primary care interval is de-
fined as the time from the patient’s first presentation in
primary care until referral to secondary care; the diag-
nostic interval is defined as the time from the first pres-
entation until decisive diagnosis [25].
The secondary outcome was the stage at diagnosis as
stated in a multidisciplinary team’s decision on the clinical
TNM (cTNM) stage. The cancer stage was re-grouped
into stage IA, 1B, IIA, IIB, IIIA, IIIB and IV from the
TNM (version 7). The stage was then dichotomised into
local and advanced using a cut-point between stage IIIA
and IIIB. This was done as there is a significant difference
in mortality between these two stages [26].
As a naturally derived effect of the new diagnostic mo-
dality combined with a CME focusing on lung cancer
diagnosis, we wanted to test whether there was a differ-
ence in the use of the existing fast-track and the PPV for
lung cancer in the fast-track between intervention and
control GPs. Patients referred to fast-track evaluation for
lung cancer were coded DZ 03.1B (lung cancer observa-
tion). This code, combined with a unique GP number,
gave information about referral to the fast-track pathway.
Variables and data sources
All cases of lung cancer (ICD10 34.0–9) were identified
starting from 1 January 2012. To ensure completeness,
cases were obtained from a combined identification in
the Danish Lung Cancer Registry (DLCR) and the
Danish National Patient Registry (NPR). The lung cancer
cases were checked against practice patient lists in order
to identify the patients’ GPs. From these lists, we also
gathered information about the size of the practice lists
and the age and gender distributions of the patients
listed with each practice.
The DLCR was established in 2001 as a national data-
base. Since 2003, data have covered more than 90 % of all
lung cancer cases in Denmark [27]. Registrations are made
electronically and no later than two months after diagno-
sis. The NPR is a national population-based database con-
taining admission/discharge dates and discharge diagnosis
(classified according to the International Classification of
Diseases, ICD-10) on all inpatient, outpatient clinics and
emergency room visits at Danish hospitals [28].
We used the Danish Deprivation Index (DADI) to
gather information about deprivation level in the differ-
ent GP clinics’ populations. The index consists of eight
variables registered in Statistics Denmark for all citizens
[29]. The DADI data are expressed numerically as a
value between 10 and 100; the higher the number, the
more deprived the practice population. The variables
used are: (i) Proportion of adults aged 20–59 with no
employment, (ii) proportion of adults aged 25–59 with
no professional education, (iii) proportion of adults aged
25–59 with low income, (iv) proportion of adults aged
18–59 receiving public welfare payments (transfer in-
come or social benefits), (v) proportion of children from
parents with no education and no professional skills, (vi)
proportion of immigrants, (vii) proportion of adults aged
30+ living alone and (viii) proportion of adults aged 70+
with low income (= the lowest national quartile).
Data on patient comorbidity were obtained from a GP
questionnaire in which the GP stated if comorbidity was
present or not. Data on each identified lung cancer pa-
tient’s socio-economic position were collected from
Statistics Denmark. Education included basic school and
was dichotomised into “≤10 years” and “>10 years” [30].
Marital status was dichotomised into “cohabitating” or
“living alone”.
The Danish civil registration number (CRN), a unique
10-digit personal identification number, was used to link
registers [31].
GP questionnaire
A questionnaire was sent to the lung cancer patient’s
general practice. In practices with more than one GP, we
asked the GP most familiar with the patient to complete
the questionnaire. The GPs were told to use their med-
ical records when answering questions about whether
the general practice/GP had been involved in the diag-
nosis of the lung cancer, together with the dates in the
diagnostic pathway and the use of a fast-track pathway.
The questionnaire was based on previously used and val-
idated items [16, 23, 25, 32]. Non-responders received a
reminder after 4 weeks. The responding doctors got a
reimbursement for participation (€17, £15).
Statistical methods
Pearson’s chi-squared test or Wilcoxon rank-test were
used for comparison of patients listed with either inter-
vention or control GPs in terms of baseline characteris-
tics as well as for the crude analysis of study outcomes.
Primary analyses were by standard intention-to-treat
with participants analysed according to their GP’s ran-
domisation. The primary care and the diagnostic interval
are presented as medians with inter-quartile intervals
(IQI). We used general linear models (GLM) for the bi-
nomial family to calculate associations between long
intervals and the patients’ randomisation status. Long in-
tervals were defined as the 4th quartile of similar inter-
vals from Danish lung cancer patients in 2010 [33]. In
these analyses, we accounted for clusters of patients
within GPs using cluster robust variance estimation and
adjusted for patient age and presence of comorbidity as
it has previously been shown that these factors can influ-
ence the length of the intervals [33].
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In supplementary analyses, we corrected for non-
compliance by comparing patients from GPs who partic-
ipated in the CME with patients from a similar group of
patients from control GPs [34]. These estimates are not
diluted by lack of compliance as they are standard in
intent-to-treat analyses.
Referral rates were calculated based on the number of
patients referred by the GP per project month per patient
aged 25 years and above. For the non-compliance analyses
on referral rates, we used the risk of having a low referral
rate (defined as among the 25 % lowest referral rates for
the two groups together).
Estimates were presented with 95 % confidence inter-
vals (95 % CI) when relevant. Analyses were made using
Stata 12.0.
Numbers analysed
Descriptive analyses and analyses on cancer stage were
performed for the entire study population. The analysis
of time intervals was restricted to patients for whom the
GP returned the questionnaire and for whom the GP
was involved in the diagnosis.
Ethics
The study was approved by the Danish Data Protection
Agency (ref. no.: 2011-41-6872) and the Danish Health
and Medicines Authority (ref. no.: 7-604-04-2/357/
KWH). According to the Research Ethics Committee of
the Central Denmark Region, the Danish Act on Re-
search Ethics Review of Health Research Projects did
not apply to this project (ref.no.: 118/2011) as CT was
already a widely used technology. The study is registered
at Clinical Trials (www.clinicaltrials.gov: NCT01527214).
Results
Participants flow
During the study period, 331 incident lung cancer patients
were diagnosed; 171 were listed with intervention GPs and
160 with control GPs (Fig. 1). In the intervention group,
80.1 % (137 patients) of the GP questionnaires were
returned; in the control group, 81.9 % (131 patients). Inter-
vention GPs were involved in the lung cancer diagnosis of
97 patients (70.8 %, 95 % CI: 62.4–78.3), whereas the GPs
in the control group were involved in the diagnosis of 82
patients (62.6 %, 95 % CI: 53.7–70.9) (p = 0.154) (Fig. 1).
Baseline data
The GPs in the intervention group were slightly older
(mean 53.6 years compared with 51.6 years), their pa-
tients were slightly more deprived and more were work-
ing in a solo practice (Table 1). Sixty-four (48.5 %) of the
GPs who were offered CME participated.
Lung cancer patients from the intervention and the
control GPs were similar with respect to age, education,
marital status and comorbidity, while the control group
had a higher proportion of women (Table 2). No statisti-
cally significant differences between the intervention and
the control group patients for which the GPs returned
the questionnaire were observed (Appendix).
Primary outcomes: the primary care and the diagnostic
intervals
For all patients, the median primary care interval was
16 days (IQI: 4–56) (Table 3). There was no statistically sig-
nificant difference in primary care interval between patients
in the intervention group (median: 14 days, IQI: 4–53) and
patients in the control group (median: 18 days, IQI: 5–69).
The overall median diagnostic interval was 39 days
(IQI: 17–93). Patients listed with control GPs had a sta-
tistically insignificantly longer median diagnostic interval
(44 days, IQI: 17–112) than patients listed with interven-
tion GPs (36 days, IQI: 17–83) (p = 0.299).
There was no difference in the proportions experiencing
long primary care or diagnostic intervals between patients
from the control and the intervention groups. Within the
intervention group, both primary care and diagnostic in-
tervals were statistically significantly shorter if the GP (or
a GP in the clinic) participated in the CME (primary care
interval median: 9 days vs. 37 days, p = 0.048; diagnostic
interval median: 23 vs. 66, p = 0.008).
Correcting for non-compliance, we found a statistically
insignificantly higher risk for having a long diagnostic
interval for patients from the control group (risk
Table 1 Baseline characteristics of GPs in the control and
intervention groups. Numbers with (percentages) unless stated
otherwise
GP intervention GP control
All GPs 133 133
All practice 60 59
Gender:
Male 68 (51.1) 64 (48.1)
Female 65 (48.9) 69 (51.9)
Age:
Mean (min-max) 53.6 (38–68) 51.6 (38–65)
38–45 yrs. 26 (19.5) 23 (17.3)
46–55 yrs. 67 (50.4) 52 (39.1)
56–68 yrs. 40 (30.1) 58 (43.6)
Practice type:
Solo 21 (35.0) 16 (27.1)
2 or more 39 (65.0) 43 (72.9)
List size/GPa, Median (range) 1008 (585–2780) 992 (500–3347)
DADIb, Median (IQR) 25.4 (20.5–31.6) 22.5 (18.5–30.8)
CME participation 64 (48.5)
aList size per GP (patients aged ≥25 years). bDanish Deprivation
Index (min:10-max:100)
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Table 2 Characteristics of the lung cancer patients. All patients, patients from control and intervention GPs, and patients for whom the GP was involved in the diagnosis of the
lung cancer
All patients Intervention all Control all P-value Intervention, GP involved Control, GP involved p-value
n (%) n (%) n (%) n (%) n (%)
All: n 331 171 (51.7) 160 (48.3) 97 (70.8) 82
Gender:
Male 157 (47.4) 91 (53.2) 66 (41.3) 0.029a 46 (47.4) 40 (48.8) 0.459a
Female 174 (52.6) 80 (46.8) 94 (58.7) 51 (52.6) 42 (51.2)
Age:
Mean (95%CI) 69.4 (68.4–70.5) 69.6 (68.1–70.5) 69.3 (67.7–70.8) 0.799a 69.8 (67.8–71.7) 68.3 (66.2–70.4) 0.830b
Range 40–97 yrs. 40–97 yrs. 44–86 yrs. 45–89 yrs. 44–86 yrs.
40–59 yrs 61 (18.4) 33 (19.3) 28 (17.5) 0.904b 19 (47.5) 16 (19.5) 0.440c
60–79 yrs 222 (67.0) 111 (64.9) 111 (69.4) 63 (64.9) 59 (72.0)
80+ 48 (14.5) 27 (15.8) 21 (13.1) 15 (15.4) 7 (8.5)
Education:
<10 yrs 136 (41.1) 67 (39.2) 69 (43.1) 0.733b 35 (36.1) 37 (45.1) 0.434c
10–15 146 (44.1) 77 (45.0) 69 (43.1) 45 (46.4) 33 (40.3)
>15 yrs 40 (12.1) 20 (11.7) 20 (12.5) 13 (13.4) 11 (13.4)
Unknown 9 (2.7) 7 (4.1) 2 (1.3) 4 (4.1) 1 (1.2)
Marital status
Cohabitating 172 (52.0) 88 (51.5) 84 (52.5) 0.850a 55 (56.7) 44 (53.7) 0.422a
Living alone 159 (48.0) 83 (48.5) 76 (47.5) 42 (43.3) 38 (46.3)
Comorbidity -questionnaire
Yes 231 (69.8) 83 (85.6) 69 (84.1) 0.663a
No 35 (10.6) 13 (13.4) 13 (15.9)
Unknown 65 (19.6) 1 (1.0) 0












Table 3 Primary care and diagnostic intervals (in days) for lung cancer patients with a referral route involving the GP, according to groups. Only GP-involved patients are included in
the analyses. Adjusted and unadjusted associations for long intervals (the 75 percentile from 2010) are presented as prevalence ratios (PRs) with 95 % confidence intervals (95 % CI)
Primary care interval: Diagnostic interval:




PR (95 % CI)
Unadjusted
PR (95 % CI)
adjusteda




PR (95 % CI)
Unadjusted
PR (95 % CI)
adjusteda
All 155 16 4–
56
36.1 (28.6–44.2) 160 39 17–93 33.1 (25.9–41.0)
Controls 74 18 5–
69
36.5 (25.6–48.5) 1 1 75 44 17–
112
37.3 (26.4–49.3) 1 1
Intervention 81 14 4–
53
0.455d 35.8 (25.4–47.2) 0.98 (0.65–1.49) 0.99 (0.65–1.54) 85 36 17–83 0.299d 29.4 (20.0–40.3) 0.79 (0.51–1.23) 0.80 (0.50–1.27)
Intervention:
- CMEb 32 37 8–
61
53.1 (34.7–70.9) 1 1 35 66 22–
143
42.9 (26.3–60.6) 1 1
+ CMEc 49 9 3–
27
0.048d 24.5 (13.3–38.9) 0.46 (0.26–0.83) 0.49 (0.27–0.88) 50 23 15–50 0.008d 20.0 (10.0–33.7) 0.47 (0.24–0.92) 0.45 (0.20–1.03)
aAdjusted for patient age and co-morbidity (yes/no). Clusters are accounted for. bThe GPs who did not participate in CME or who did not work in a clinic with a GP who participated. cThe GPs participating in CME or












difference (RD): 13.5 % (95 % CI:−11.0–37.9 %, p-value
= 0.280)). No difference in risk for having a long primary
care interval was observed using this approach (RD:
1.1 % (95 % CI: 123.9–26.1 %, p-value = 0.929)).
Secondary outcomes: stage
A total of 41.4 % of all lung cancer patients were in a
localised stage. There was no difference in stage distribu-
tion between patients from the control and the interven-
tion GPs in the non-adjusted analyses (Table 4). We found
no difference in the risk of having localised stage when
adjusting for non-compliance (RD: 1.5, 95 % CI:−31.8–
34.9, p value = 0.927).
General effects on other diagnostic stategies
The GPs referred 836 patients to the lung cancer fast-track
during the study period which resulted in 81 lung cancer
diagnoses. This corresponds to a PPV of 9.7 % (10.1 % for
control GPs and 9.4 % for intervention GPs; p-value: 0.732)
for lung cancer diagnosed via the fast-track lung cancer
pathway. The unadjusted referral rate to fast-track was 0.17
per 1000 adults listed per GP per month (95 % CI: 0.12–
0.25) for intervention patients compared with 0.15 (95 %
CI: 0.11–0.24) for control GPs (p-value: 0.417). When cor-
recting for non-compliance, we found no difference in PPV
between the two groups (RD: 1.1 % (95 % CI:−5.8–8.2, p =
value: 0.740)), but a statistically insignificantly higher risk
for having a low referral rate (below the lowest referral rate




In a cluster-randomised trial with a combination of CME
and direct access to LDCT, we found no statistically signifi-
cant difference in primary care or diagnostic intervals be-
tween patients listed with the control and the intervention
GPs. However, when correcting for non-compliance, we
found that the patients were at higher risk of experiencing
a long diagnostic interval if their GPs were in the control
group. There was no difference between the groups in
terms of stage, the use of the fast-track pathway or the PPV
for lung cancer.
Strength and limitations
This study is, to the authors’ knowledge, the first randomised
controlled trial testing the effect of direct access to low-dose
CT from primary care. The study design of randomising by
clusters at the level of general practice address (and not at
the level of patient or clinician) was appropriate to the re-
search question. It would not be possible to ask the GP to al-
locate individual patients randomly, and allocating individual
GPs within a practice would invite a risk of spill over [22].
A major strength of this study is the well-defined study
population and the large number of patients. The re-
sponse rate for GP questionnaires was high. The data ob-
tained in the registries were complete, as were data on GP
participation in the CME.
The high response rate of 81.0 % minimises the risk of
selection bias, as seen also by the similarity of the lung
cancer patients in the control and the intervention group.
However, patients who were not included due to GP non-
response may differ from patients of responding GPs in
respect of diagnostic intervals.
A potential risk of information bias exists due to GP re-
call bias. However, the GPs were asked to answer the ques-
tionnaire based on their electronic records. We would not
expect such recall bias to be unevenly distributed between
the two randomised groups although GPs in the interven-
tion group who participated in the CME might estimate
the intervals even longer than the control GPs because they
had recently received an up-date on lung cancer symptoms
and their awareness of such symptoms in the daily practice
would hence be heightened. This bias will underestimate a
Table 4 Stage distribution for patients in the study (all patients dived between intervention and controls), and only for patients for
whom the GP was involved in the diagnosis
All patients Controls, all Intervention, all P-value Controls, involved Intervention, involved p-value
n (%) n (%) n (%) n (%) n (%)
Stage IA 46 (13.9) 19 (11.9) 27 (15.8) 4 (4.9) 11 (11.3)
Stage IB 33 (10.0) 18 (11.3) 15 (8.8) 8 (9.8) 8 (8.3)
Stage IIA 14 (4.2) 3 (1.9) 3 (1.8) 3 (3.7) 3 (3.1)
Stage IIB 22 (6.6) 11 (6.9) 11 (6.4) 7 (8.5) 7 (7.2)
Stage IIIA 22 (6.6) 9 (5.5) 13 (7.6) 5 (6.1) 6 (6.2)
Stage IIIB 24 (7.3) 12 (7.5) 12 (7.0) 7 (8.5) 9 (9.3)
Stage IV 170 (51.4) 88 (55.0) 90 (52.6) 0.586a 48 (58.5) 53 (54.6) 0.470a
Localised (IA-IIIA) 137 (41.4) 60 (37.5) 69 (40.4) 0.595b 27 (32.9) 35 (36.1) 0.658b
Metastatic (IIIB-IV) 194 (58.6) 100 (62.5) 102 (59.6) 55 (67.1) 62 (63.9)
aDifferences between groups were tested by Wilcoxon test.bDifferences between groups were tested by Pearsons χ2 test
Guldbrandt et al. BMC Cancer  (2015) 15:934 Page 8 of 11
possible effect of the intervention on the two intervals. This
could explain the non-significant difference in the primary
care interval between the two groups.
Unfortunately, only about half of the invited GPs
participated in the CME. The correction for non-
compliance addresses this problem, but the analyses increase
the uncertainty of the estimates and the study may hence be
underpowered because the low participation rate of GPs
was duly catered for in our sample size calculation. Still, the
risk of experiencing a long diagnostic interval was 13 %
higher in the control group than in the intervention group
that also participated in the CME. This means that CME
combined with direct access to CT may have expedited
diagnosis, but a larger study is needed to fully evaluate the
effect as we cannot disprove the null-hypothesis.
The study may be underpowered due to two additional el-
ements. The LDCT part of the intervention would have the
most impact in the diagnosis of patients who present with
false negative X-rays. A false negative X-ray constitutes a
major risk of delay of diagnosis and may occur in approxi-
mately 20 % of patients preceding diagnosis. When taking
this into account the sample size may have been five times
as large than the one we calculated. However, the CME
aimed at increasing the GPs awareness of early lung cancer
and encouraging the GPs to refer more patients to test
which together would decrease time to diagnosis. Further-
more, hoping for a stage shift in diagnosed lung cancers was
maybe a bit optimistic. When planning the study we calcu-
lated that more lung cancer patients would have been diag-
nosed by the LDCT. If so these patients would constitute a
larger proportion of the lung cancers from the intervention
GPs and thereby increasing the chance of a stage shift.
The intervention GPs in this study were offered a 1 h
lung cancer up-date. Those who agreed to participate may
have been more interested in lung cancer, and this group of
GPs may already have performed better in diagnosing lung
cancer, which would potentially underestimate the effect of
training if it was generalised. We did find that the patients
of intervention GPs participating in the CME had much
shorter intervals than patients of non-participating GPs.
This either implies that the intervention was a success or
that the intervention GPs who received CME already per-
formed better than the rest of the intervention group.
The intervention group referred statistically insignifi-
cantly more patients to the fast-track pathway but the PPV
for lung cancer was identical in the two groups of GPs.
This may indicate that CME has a positive effect by making
the GPs refer more patients to diagnostics. The PPV was
the same although an extra CT-scan was an option, which
may suggest that intervention GPs were able to find more
cancer patients in their practices, maybe because of a
greater awareness of lung cancer signs and symptoms.
The present study utilised low-dose CT as the diagnostic
tool. For lung cancer, CT has a high sensitivity, but a lower
specificity. This implies that the method involves a risk of pa-
tient distress because of the relatively high number of false
positive scans. Furthermore, a widespread concern is the risk
of cancer secondary to radiation from the low-dose CTs and
the subsequent imaging used to evaluate positive screens. A
US study from 2013 addresses this problem in connection
with low-dose CTscreening studies [35]. Based on epidemio-
logical data on radiation exposure and assuming annual low-
dose CT from age 55 to age 74 (20 scans), they estimate a
lifetime attributable risk of lung cancer mortality of 0.07 %
for males and 0.14 for females. One single low-dose CT uti-
lises not even half of the total annual radiation exposure
from natural and man-made sources. In addition, the group
of patients referred to a low-dose CT may have a higher risk
of having lung cancer or other important diseases than other
groups of patients, and the small radiation dose (potential in-
ducing a cancer 20–30 years later) may contribute only very
little to the other risks these patients are facing.
Generalisability
This Danish single-setting randomised, controlled trial
with complete inclusion of patients holds the opportunity
to generalise the study results to other settings in which
general practice serves as the first line of healthcare.
Comparison with relevant literature
In the present study, the median primary care interval
was 16 days which is longer than the similar Danish
interval in 2010 (median 7 days, IQI: 0–30) [33].
Whether this means that the diagnosis of lung cancer is
less expedite in 2012–2013 than in 2010 is unknown,
but we suggest that it may rather be because of in-
creased awareness of lung cancer symptoms and early
diagnosis and therefore an earlier first symptom presen-
tation date listed in the questionnaire.
The patients listed at CME participating GPs has shorter
diagnostic intervals than patients listed at non-participating
GPs. These findings are in line with results from a British
study in 2012 [5]. The study showed that a simple informa-
tion campaign could educate physicians (and the public)
and thereby induce change in behavior and increase the
chest X-ray referral rate. The positive results on CME in this
study holds potential for CME as a tool for earlier cancer
diagnosis and need evaluation in a larger study concerning
cancer CME in primary care. Such study has been con-
ducted in Denmark and we are awaiting the results [36].
In the present study, 15 lung cancers were diagnosed in
648 direct CT scans from primary care (2.3 %) (24). Be-
cause of the symptomatic presentation, more lung cancers
are diagnosed than by screening. In the US screening trial,
lung cancer was diagnosed in 0.7 % of screenings [2], in the
Danish screening trial the incidence was 0.8 % [3]. This
suggests that use of CT scan in symptomatic patients per-
forms better than screening.
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Conclusions
This randomised, controlled study with direct access to low-
dose CT and CME intervention had no statistically significant
effect on time to diagnosis or stage at diagnosis in lung cancer
patients. However, it could have an effect in a larger scale
study with more statistical power. Also, we do not know how
direct CT will perform in terms of patient/doctor satisfaction
and in connection with diagnosis of other lung diseases; these
issues were beyond the scope of the present study. Direct ac-
cess to low-dose CTscan may be an alternative to lung cancer
screening. Furthermore, a recommendation of low-dose CT
screening should consider offering symptomatic, unscreened
patients access to CT directly from primary care. The positive
results from the CME on early lung cancer diagnosis holds
potential for further studies in this important field.
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